Koers VG Life Sciences Inc. Other OTC
Aandelen
VGLS
US91822T1016
Biotechnologie & Medisch Onderzoek
Omzet 2013 | - | Omzet 2014 | - | Marktkapitalisatie | 2,23 mln. 2,08 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -7 mln. -6,54 mln. | Nettowinst (verlies) 2014 | -6 mln. -5,6 mln. | EV/omzet 2013 | - |
Nettoschuld 2013 | 2,49 mln. 2,33 mln. | Nettoschuld 2014 | 3,83 mln. 3,57 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-0,25
x | K/w-verhouding 2014 |
-0,31
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Ana Gois
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,65% | 39,36 mld. | |
-8,62% | 38,52 mld. | |
+26,95% | 30,74 mld. | |
+10,74% | 25,92 mld. | |
-13,50% | 26,03 mld. | |
+44,87% | 14,13 mld. | |
+34,36% | 12,73 mld. | |
-7,14% | 11,29 mld. | |
-12,61% | 10,64 mld. |